Today: October 6, 2015, 6:27 pm

Global PTH(1-31)NH2 market: Latest market analysis presented
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 - a new market research report on 2014-03-14 03:03:01
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 - We have released our new PharmaPoint Drug Evaluation report, "PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the gold-standard bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lillys blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.

PTH(1-31)NH2 is an oral PTH analog being developed by Unigene Laboratories. Like Lillys marketed PTH, Forteo, PTH(1-31)NH2 is an anabolic drug that stimulates bone formation. It has the opportunity to be combined with an antiresorptive drug to create a powerful dual-action treatment approach. The drug was previously in development under an exclusive worldwide licensing agreement with GSK, which included Unigenes provision of development and clinical supply services, but GSK terminated the agreement in December 2011 shortly after the top-line Phase II trial results were released (Unigene Laboratories, press release, December 5, 2011). At that time, Unigene indicated its intention to find a development partner and licensee for the drug.

Note: This is upcoming report and will be delivered within 24 hrs of the purchase (excluding weekends).


- Overview of Osteoporosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on PTH(1-31)NH2 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for PTH(1-31)NH2 for the top six countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain and the UK

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of PTH(1-31)NH2 performance
- Obtain sales forecast for PTH(1-31)NH2 from 2012-2022 in top six countries (the US, France, Germany, Italy, Spain and the UK)

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 703 Words
Related Articles
More From Finance
Credit-Yogi Teaches Consumers How To Use HAMP [..]
Be Prepared to Utilize HAMP Lenders do not like to help borrowers prevent foreclosure by accessing the Obama loan modification [..]
Credit-Yogi Informs Military Members Facing Auto Repossession [..]
No one wants to have their vehicle taken back by their banks. It’s a source of stress for the individual [..]
Credit-Yogi .com Teaches Consumers How To Prevent [..]
Want to Halt Vehicle Repossession? Here’s How Sometimes things happen that end up leaving one in a financially strapped position. [..]
Sell Your Phoenix Winter Condo or Townhouse [..]
Most condominium owners or homeowners, in almost every state in the country, are asking the same question: “Should I sell [..] Shows Homeowners How To Avoid Foreclosure [..]
The idea that someone could lose his home to his lender is just scary, and he may not know how [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.